Lisa Coleman

Lisa Coleman serves as a key procurement professional within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through strategic acquisitions of scientific and technical services. She manages a portfolio of research and development contracts focused on advancing biomedical innovation, including experimental therapeutics, diagnostic platforms, and translational science initiatives. Her work directly enables the NCI’s priority areas in precision medicine and high-impact biomedical discovery by ensuring timely, compliant access to specialized research capabilities. She typically handles complex, performance-based acquisitions under full and open competition, emphasizing scientific rigor and technical feasibility in source selection. Her primary contractor relationship is with Quality Biological, Inc., a leading provider of biological reagents, cell lines, and research-grade materials critical to preclinical and laboratory-based cancer studies. Coleman’s procurement pattern reflects a sustained, high-volume reliance on this vendor for standardized yet highly specialized biological products essential to reproducible research. While she maintains a primary partnership with Quality Biological, her acquisition strategy supports a broader ecosystem of scientific suppliers capable of meeting stringent quality and regulatory standards required for NIH-funded research. Coleman’s contracting activity is entirely under full and open competition, with no set-asides designated for 8(a), HUBZone, SDVOSB, or other socioeconomic programs. This reflects the NCI’s operational emphasis on technical capability and scientific validity over socioeconomic preferences, prioritizing access to the most qualified providers regardless of business size or certification status. Her approach aligns with the institute’s mission-critical need for consistent, high-purity research materials and specialized services that meet exacting federal biosafety and compliance benchmarks. Her procurement focus is exclusively under NAICS 541715, which encompasses research and development in the life sciences. She procures advanced biological reagents, analytical instrumentation, and specialized laboratory services supporting molecular oncology, genomic profiling, and preclinical drug development. Her domain expertise lies in the intersection of scientific research requirements and federal acquisition regulations, ensuring that procurement actions directly enable cutting-edge cancer research without compromising compliance or scientific integrity.